How Investors Are Reacting To uniQure (QURE) After Its Pivotal FDA Type A Meeting On AMT-130

Qure has previously announced that it held a Type A meeting with the U.S. Food and Drug Administration to discuss the ...
Nasdaq

uniQure N.V. Reports Progress with AMT-130 for Huntington’s Disease and Updates on Clinical Trials Across its Gene Therapy Pipeline

Announced alignment with the U.S. FDA on key elements of the Accelerated Approval pathway for AMT-130 in Huntington’s disease, moving closer to the potential approval of a disease-modifying treatment.
FiercePharma

AMT's Marketing Authorisation Application for Glybera(R) Progressing on Schedule

AMT expressly disclaims any intent or obligation to update these forward-looking statements except as required by law. For a more detailed description of the risk factors and uncertainties affecting ...
Nasdaq

uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-191 Gene Therapy for Fabry Disease

LEXINGTON, Mass. and AMSTERDAM, Nov. 29, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, ...
Seeking Alpha

uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-260 Gene Therapy for Refractory Mesial Temporal Lobe Epilepsy

LEXINGTON, Mass. and AMSTERDAM, Sept. 05, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs ...